Meta Information
ID:inclisiran
Name:
Schema Version:AIM-2.0
Interactions
Target id:
/class/statins
Target name:
Statins (HMG-CoA Reductase Inhibitors)
Severity:
major
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Statins increase the number of LDL receptors on liver cells, while inclisiran prevents the breakdown of these receptors. This dual mechanism leads to a powerful, synergistic reduction in LDL cholesterol.
Actionable advice:
Use in combination with a statin, as prescribed, for maximal LDL-lowering benefit.
Target id:
/intervention/ezetimibe
Target name:
Ezetimibe
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Ezetimibe reduces cholesterol absorption from the gut, which signals the liver to increase LDL receptors. Inclisiran enhances this effect by preventing receptor breakdown, providing an additional LDL-lowering effect.
Actionable advice:
Can be effectively combined with ezetimibe for further LDL cholesterol reduction.
Target id:
/intervention/bempedoic-acid
Target name:
Bempedoic Acid
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Bempedoic acid inhibits cholesterol synthesis in the liver upstream of statins, leading to an increase in LDL receptors. This effect is complementary to inclisiran's mechanism, resulting in enhanced LDL lowering.
Actionable advice:
May be used in combination with bempedoic acid for an additive LDL-lowering effect, especially in statin-intolerant patients.
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Cholesterol is essential for normal fetal development. All lipid-lowering therapies, including inclisiran, are generally contraindicated during pregnancy due to theoretical risks to the fetus.
Actionable advice:
Avoid completely during pregnancy and discontinue before attempting to conceive.
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is unknown if inclisiran is present in human milk or what its effects might be on a nursing infant. Due to the potential for adverse effects, it is contraindicated during breastfeeding.
Actionable advice:
Do not use while breastfeeding.
Target id:
/condition/hepatic-impairment
Target name:
Severe Hepatic Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Inclisiran has not been studied in patients with severe liver disease (Child-Pugh class C). Its safety and efficacy in this population are unknown, and caution is advised as the liver is its site of action.
Actionable advice:
Use with caution and under specialist supervision in severe liver disease; it may be contraindicated.
Target id:
/intervention/mediterranean-diet
Target name:
Heart-Healthy Diet (e.g., Mediterranean, DASH)
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
A diet low in saturated/trans fats and high in fiber supports the LDL-lowering goals of inclisiran therapy, leading to better overall cardiovascular outcomes.
Actionable advice:
Adopt a heart-healthy diet to complement the medication's effects and improve cardiovascular health.
Target id:
/dietary/high-fat-meal
Target name:
Diet High in Saturated and Trans Fats
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Consuming a diet high in saturated and trans fats actively raises LDL cholesterol, which directly counteracts the therapeutic effect and goal of inclisiran treatment.
Actionable advice:
Avoid diets high in saturated and trans fats as they work against the medication's intended purpose.
Target id:
/biomarker/apolipoprotein-b
Target name:
Apolipoprotein B (ApoB) and LDL-C
Severity:
major
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Inclisiran is designed to potently lower levels of LDL cholesterol and its primary carrier protein, ApoB. Monitoring these biomarkers is essential to confirm the drug is working as intended.
Actionable advice:
Regularly monitor ApoB and LDL-C levels to confirm the therapeutic efficacy of the treatment.
Target id:
/biomarker/alanine-aminotransferase
Target name:
Liver Enzymes (ALT/AST)
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Inclisiran can cause mild, temporary increases in liver enzymes (transaminases) in a small percentage of patients, though this is rarely clinically significant.
Actionable advice:
Monitor liver function tests periodically as recommended by your physician.
Target id:
/class/cyp3a4-substrates
Target name:
Drugs Metabolized by Cytochrome P450 Enzymes
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Inclisiran is an siRNA therapeutic not metabolized by the cytochrome P450 system, meaning it does not have clinically significant pharmacokinetic interactions with the vast majority of other drugs.
Actionable advice:
No dose adjustments are needed for other medications based on metabolic pathways, simplifying co-administration.